These pathways converge on shared effectors like FN1 and CCND1, as identified in our ceRNA network, reinforcing their relevance to the miR-145 axis and highlighting opportunities for combinatorial therapeutic strategies in NSCLC. The gene discussed is FN1; the disease is non-small cell lung carcinoma.